The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ermokhina L.V.

Federal Research and Clinical Center of Reanimatology and Rehabilitation;
Demikhov Moscow City Clinical Hospital

Berikashvili L.B.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Yadgarov M.Ya.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Chaus N.I.

Demikhov Moscow City Clinical Hospital

Baeva A.A.

Federal Research and Clinical Center for Intensive Care and Rehabilitation

Melnikova N.S.

Demikhov Moscow City Clinical Hospital

Perehodov S.N.

City Clinical Hospital named after V.P. Demihov of the Moscow City Health Department

Kuzovlev A.N.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Impact of cardiovascular diseases and their therapy on mortality of ICU patients with COVID-19

Authors:

Ermokhina L.V., Berikashvili L.B., Yadgarov M.Ya., Chaus N.I., Baeva A.A., Melnikova N.S., Perehodov S.N., Kuzovlev A.N.

More about the authors

Journal: Russian Journal of Anesthesiology and Reanimatology. 2022;(1): 36‑43

DOI: 10.17116/anaesthesiology202201136

Read: 4129 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

IMPACT OF CARDIOVASCULAR DISEASES AND THEIR THERAPY ON MORTALITY OF ICU PATIENTS WITH COVID-19
IMPACT OF CARDIOVASCULAR DISEASES AND THEIR THERAPY ON MORTALITY OF ICU PATIENTS WITH COVID-19

To cite this article:

Ermokhina LV, Berikashvili LB, Yadgarov MYa, et al. . Impact of cardiovascular diseases and their therapy on mortality of ICU patients with COVID-19. Russian Journal of Anesthesiology and Reanimatology. 2022;(1):36‑43. (In Russ., In Engl.)
https://doi.org/10.17116/anaesthesiology202201136

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sele­ctive anosmia for mono­molecular odorants in a cohort of young indi­viduals. Russian Rhinology. 2024;(4):262-268
The resu­lts of the examination of patients with chro­nic gene­ralized periodontitis after novel coro­navirus infe­ction. Russian Journal of Stomatology. 2024;(4):18-22
Waiting for Disease X: a plan for preparing Russian labo­ratory services for the next pandemic. Labo­ratory Service. 2024;(4):5-11
Personalized approach to treatment choice using a digi­tal profile of patient with cardiovascular diseases: the features of clinical deci­sion-making support service. Russian Cardiology Bulletin. 2024;(4-2):105-112
A pilot study of the rela­tionship between cardiovascular risk and routine mammography data in women. Russian Cardiology Bulletin. 2024;(4-2):154-160
Diffuse changes in the brain in the acute phase of COVID-19 and after infe­ction. Russian Journal of Archive of Pathology. 2025;(1):5-15
Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Abstract:

There are various data on negative impact of comorbidities on treatment outcomes in patients with novel coronavirus infection (COVID-19). However, the impact of cardiovascular diseases and especially their therapy on the course of infectious process and unfavorable outcomes in COVID-19patients has not been sufficiently studied.

OBJECTIVE

To assess the impact of concomitant cardiovascular diseases and chronic drug intake for their treatment on in-hospital mortality in ICU patients with COVID-19.

MATERIAL AND METHODS

A single-center retrospective cohort study of ICU patients with COVID-19 was carried out between March 6, 2020 and June 3, 2020 at the Demikhov Moscow City Clinical Hospital. We analyzed the following data: age, gender, previous comorbidities, Charlson comorbidity index, therapy of chronic cardiovascular diseases, severity of COVID-19, NEWS and SOFA scores. Univariate analysis included assessment of relative risk (RR). Multivariate analysis was carried out using regression model.

RESULTS

We analyzed medical records of 403 patients (231 (57.3%) men). Mean age of patients was 62.4±15.3 years. Overall 30-day mortality rate was 44.9% (n=181). Multivariate analysis showed that coronary artery disease (adj. OR 2.459, 95% CI 1.589—3.806, p<0.001) and hypertension (adj. OR 2.893, 95% CI 1.667—5.019, p<0.001) were independent predictors of mortality in ICU patients with COVID-19.

CONCLUSION

Coronary artery disease and hypertension are independent predictors of poor outcomes. Long-term use of angiotensin-converting enzyme inhibitors, β-blockers, acetylsalicylic acid or statins for cardiovascular diseases does not significantly affect clinical outcomes in ICU patients with COVID-19.

Keywords:

COVID-19
cardiovascular diseases
hypertension
angiotensin-converting enzyme inhibitors
β-blockers
acetylsalicylic acid
statins

Authors:

Ermokhina L.V.

Federal Research and Clinical Center of Reanimatology and Rehabilitation;
Demikhov Moscow City Clinical Hospital

Berikashvili L.B.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Yadgarov M.Ya.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Chaus N.I.

Demikhov Moscow City Clinical Hospital

Baeva A.A.

Federal Research and Clinical Center for Intensive Care and Rehabilitation

Melnikova N.S.

Demikhov Moscow City Clinical Hospital

Perehodov S.N.

City Clinical Hospital named after V.P. Demihov of the Moscow City Health Department

Kuzovlev A.N.

Federal Scientific and Clinical Center of Intensive Care and Rehabilitation

Received:

10.08.2021

Accepted:

08.11.2021

Close metadata

References:

  1. Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 11 (07.05.2021). Ministerstvo zdravoohraneniya Rossijskoj Federacii. Accessed June 01, 2021. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/B%D0%9C%D0%A0_COVID-19.pdf
  2. Beloborodova NV, Zuev EV, Zamyatin MN, Gusarov VG. Causal Therapy of COVID-19: Critical Review and Prospects. Obshchaya reanimatologiya. 2020;16(6):65-90. (In Russ.). https://doi.org/10.15360/1813-9779-2020-4-0-1
  3. Hariyanto T, Hardyson W, Kurniawan A. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis. Drug Research. 2021;71(5):265-274.  https://doi.org/10.1055/a-1336-2371
  4. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: A Nationwide analysis. The European Respiratory Journal. 2020;55(5):2000547. https://doi.org/10.1183/13993003.00547-2020
  5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. https://doi.org/10.1001/jama.2020.2648
  6. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A, Faggiano P, Gorga E, Lombardi CM, Milesi G, Vizzardi E, Volpini M, Nodari S, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal. 2020;41(19):1821-1829. https://doi.org/10.1093/eurheartj/ehaa388
  7. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776. https://doi.org/10.1001/jama.2020.4683
  8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. https://doi.org/10.1001/jama.2020.6775
  9. Shlyahto EV, Konradi AO, Arutyunov GP, Arutyunov AG, Bautin AE, Bojcov SA, Villeval’de SV, Grigor’eva NYu, Duplyakov DV, Zvartau NE, Koziolova NA, Lebedev DS, Mal’chikova SV, Medvedeva EA, Mihajlov EN, Moiseeva OM, Orlova YaA, Pavlova TV, Pevzner DV, Petrova MM, Rebrov AP, Sitnikova MYu, Solov’eva AE, Tarlovskaya EI, Trukshina MA, Fedotov PA, Fomin IV, Hripun AV, Chesnikova AI, Shaposhnik II, Yavelov IS, Yakovlev AN. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Rossijskij kardiologicheskij zhurnal. 2020;25(3):129-148. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3801
  10. Glybochko PV, Fomin VV, Avdeev SN, Moiseev SV, Yavorovskij AG, Brovko MYu, Umbetova KT, Aliev VA, Bulanova EL, Bondarenko IB, Volkova OS, Gajnitdinova VV, Gneusheva TYu, Dubrovin KV, Kapustina VA, Kraeva VV, Merzhoeva ZM, Nuralieva GS, Nogtev PV, Panasyuk VV, Politov ME, Popov AM, Popova EN, Raspopina NA, Royuk VV, Sorokin YuD, Trushenko NV, Halikova EYu, Careva NA, Chikina SYu, Chichkova NV, Akulkina LA, Bulanov NM, Ermolova LA, Zykova AS, Kitbalyan AA, Moiseev AS, Potapov PP, Tao EA, Sholomova VI, Shchepalina AA, Yakovleva AA. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya. 2020;29(2):21-29. (In Russ.). https://doi.org/10.32756/0869-5490-2020-2-21-29
  11. ESC European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Accessed June 01, 2021. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
  12. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. Journal of Travel Medicine. 2020;27(2):taaa041. https://doi.org/10.1093/jtm/taaa041
  13. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, Widmer AF, Osswald S. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? European Heart Journal. 2020;41(19):1801-1803. https://doi.org/10.1093/eurheartj/ehaa235
  14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-116.  https://doi.org/10.1038/nature03712
  15. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory Critical Care Medicine. 2020;201(11):1380-1388. https://doi.org/10.1164/rccm.202002-0445OC
  16. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225-1228. https://doi.org/10.1016/S0140-6736(20)30627-9
  17. Sparks MA, South A, Welling P, Luther JM, Cohen J, Byrd JB, Burrell LM, Batlle D, Tomlinson L, Bhalla V, Rheault MN, Soler MJ, Swaminathan S, Hiremath S. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN. 2020;15(5):714-716.  https://doi.org/10.2215/CJN.03530320
  18. Zabolotskikh IB, Kirov MYu, Lebedinsky KM, Protsenko DN, Avdeev SN, Andrenko AA, Arsent’ev LV, Afonchikov VS, Afukov II, Belkin AA, Boeva EA, Bulanov AYu, Vasiliev YaI, Vlasenko AV, Gorbachev VI, Grigoriev EV, Grigoriev EV, Gritsan AI, Eremenko AA, Ershov EN, Zamyatin MN, Ivanova GE, Kuzovlev AN, Kulikov AV, Lakhin RE, Leiderman IN, Lenkin AI, Mazurok VA, Musaeva TS, Nikolaenko EM, Orlov YuP, Petrikov SS, Roitman EV, Ronenson AM, Smetkin AA, Sokolov AA, Stepanenko SM, Subbotin VV, Ushakova ND, Khoronenko VE, Tsarenko SV, Shifman EM, Shukevich DL, Shchegolev AV, Yaroshetskiy AI, Yarustovskiy MB. Anesthetic and resuscitation services for patients with the new coronavirus infection COVID-19. Methodical recommendations of the All-Russian public organization «Federation of anesthesiologists and resuscitators». Vestnik Intensivnoj Terapii im. A.I. Saltanova. 2021;S1:9-143. (In Russ.). https://doi.org/10.21320/1818-474X-2021-S1-9-143
  19. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382-1385. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
  20. Sarzani R. Relationship between COVID-19 and rennin-angiotensin-aldosterone-system blockers: hasty speculations may be dangerous. British Medical Journal. 2020;368:m810. https://doi.org/10.1136/bmj.m810
  21. Zabolotskikh IB, Bautin AE, Zamyatin MN, Lebedinsky KM, Potievskaya VI, Trembach NV. Perioperative management of patients with chronic heart failure. Anesteziologiya i reanimatologiya. 2021;3:6-27. (In Russ.). https://doi.org/10.17116/anaesthesiology20210316
  22. Barbarash OL, Karetnikova VN, Kashtalap VV, Zvereva TN, Kochergina AM. New coronavirus disease (COVID-19) and cardiovascular disease. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2020;9(2):17-28. (In Russ.). https://doi.org/10.17802/2306-1278-2020-9-2-17-28
  23. Libby P, Simon DL. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103(13):1718-1720. https://doi.org/10.1161/01.cir.103.13.1718
  24. Virani SS. Is There a Role For Statin Therapy in Acute Viral Infections? Accessed June 01, 2021. https://www.acc.org/latest-incardiology/articles/2020/03/18/15/09/is-there-a-role-for-statintherapy-in-acute-viral-infections-covid-19.
  25. Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS, Syrigos K. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 2021;330:114-121.  https://doi.org/10.1016/j.atherosclerosis.2021.06.911
  26. Gareeva DF, Musin TI, Pavlov VN, Davtyan PA, Ishmetov VSh, Plotnikova MR, Pavlov AV, Benzhi C, Stricker P, Carvalho K, Zagidullin NSh. Statins: unexpected help in COVID-19. Arterial’naya gipertenziya. 2020;26(5):509-517. (In Russ.). https://doi.org/10.18705/1607-419X-2020-26-5-509-517
  27. Royal College of Physicians. National Early Warning Score (NEWS) 2 2020. Accessed June 01, 2021. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 Accessed 2021-06-01
  28. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality among COVID-19 Patients: A Meta-Analysis. Journal of Community Health. 2020;45(6):1270-1282. https://doi.org/10.1007/s10900-020-00920-x
  29. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.